



Cholangiocarcinoma  
Foundation®

## Industry Council

### 2026 MEMBERSHIP PROSPECTUS

CCF kindly requests that company pledges be submitted by **January 30, 2026**. If this date does not align with your company's internal timeline, we are flexible and open to adjusting the deadline accordingly.

### About the Cholangiocarcinoma Foundation

The Cholangiocarcinoma Foundation's (CCF) mission is to find a cure and improve the quality of life for those affected by cholangiocarcinoma (CCA). Founded in 2006 in Salt Lake City, Utah, by a family that lost a loved one to cholangiocarcinoma, CCF has become a leading global resource in patient support, education, advocacy, and funding basic, clinical, and translational research. The organization's core values are patients first, collaboration, innovation, and urgency.

### About Our Industry Council Membership

The Industry Council launched on January 30, 2019, and offers companies a unique opportunity to engage with a collaborative forum of pharmaceutical and biotech firms, fostering stronger partnerships in areas of mutual interest. Five companies currently hold memberships, contributing valuable insights as we collectively prioritize key topics, share ideas, and promote cross-sector engagement. The annual membership fee of **\$40,000** includes the benefits listed below.

Membership is valid annually from January to December, but can be prorated based on the membership timeline.

### Why Become a Member

#### Strategic Engagement & Thought Leadership

##### Shape Quarterly Industry Council Meetings

Participate in 60–90 minute collaborative sessions held quarterly. Sample formats and discussion topics may include:

- *Emerging Trends & Collaborative Exchange*: Explore new developments in the field of CCA through member-driven ideation and shared learning.
- *Advisory Dialogue*: Gain real-world insights from patients or providers to inform strategies and program development.
- *Deep Dive & Expert Advisory Engagement*: Present timely company updates with the opportunity to engage in open discussion and Q&A with CCF's Scientific Medical Advisory Board (SMAB) or Nursing and Allied Health Professional Advisory Board (NAAB), allowing for expert insights and strategic feedback.
- *Year-in-Review & Strategic Outlook*: Reflect on collective impact and shape future opportunities for collaboration.

##### Direct Access to CCF Executive Leadership

Meet with CCF's executive team to discuss strategic priorities, emerging opportunities, and ways to deepen partnership impact.

### **Annual Industry Update Webinar**

Present clinical trial or treatment updates during CCF's widely attended annual webinar, which is recorded and hosted on CCF's YouTube channel for sustained visibility. On average, webinars receive an additional **300 views post-event**, with some recordings reaching over **3,000 views**—extending your company's reach and engagement with the CCA community well beyond the live session.

### **Collaborate on CCF Patient Surveys**

Contribute to survey development and data analysis to inform industry strategies and better understand the patient experience.

## Collaboration & Knowledge Exchange

### **Cross-Company Collaboration**

Partner with fellow industry leaders to address shared challenges in CCA, co-develop educational tools, and align on best practices.

### **Priority Access to the Industry Forum**

Secure premium time slots (if applicable) to present research, trial updates, or commercial programs to a panel of multidisciplinary key opinion leaders via CCF's ICRN (International CCA Research Network) at CCF's Annual Conference.

### **Access to Expert-Led Conversations**

Participate in curated discussions with scientific experts, patient advocates, and advisory boards to gain up-to-date insights on evolving trends in CCA research and care.

## Visibility & Recognition

### **Recognition on CCF Website**

Listed as an official Industry Council member, highlighting your commitment to CCA advocacy and innovation.

## Premium Event Access & Exposure

### **Premium Exhibit Booth Placement at Annual Conference**

Receive priority placement in the exhibitor hallway, ensuring high-traffic visibility as attendees enter general sessions and meals.

### **Access to the EPIC Program**

Engage directly with patients and caregivers during roundtable discussions focused on drug development, clinical trials, and treatment management.

### **Past Discussion Topics**

- Exploratory Discussion: Enhancing Informed Consent Forms for Improved Patient Understanding
- A Patient's Perspective: Diagnostic Journey, Side Effect Management, and Underreporting of Adverse Events
- Exploratory Discussion: Reaching Patients Earlier Through First-Diagnosing Clinicians, Nursing Engagement, and Timely Referrals
- Understanding Cancer of Unknown Primary: Misdiagnoses, Treatment Gaps, and Cholangiocarcinoma Impacts
- Amplifying the Patient's Voice in Early-Phase Clinical Trials: Solutions to Burdens and Barriers
- Research + Data: Inclusion/exclusion criteria and race/ethnicity in clinical trials update
- DEI (Diversity, Equity & Inclusion): Reaching Underrepresented CCA communities
- ASCO Annual Conference Highlights and Key Takeaways

## CURRENT INDUSTRY COUNCIL MEMBERS



CCF's obligation is fulfilled by delivering on the commitments articulated in this prospectus for the year indicated above, as well as by the value the sponsor receives from its association with CCF's intellectual capital, partners, and constituents.